A deep-learning serial CT biomarker improves survival prediction in immunotherapy-treated NSCLC and outperforms RECIST. Find ...

PD-L1 and alternative immune checkpoints (AICs) in non-small cell lung cancer (NSCLC): Insights into the tumor immune microenvironment (TIME) and immunotherapy (IO) outcomes. This is an ASCO Meeting ...

Characterization of TP53 mutations in actionable driver-negative non-small cell lung cancer (NSCLC). This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not ...

When many cancers advance, spread and reoccur, checkpoint inhibitors can help keep difficult tumors at bay. These antibody-based immunotherapies can restore the body’s ability to recognize and ...

Skin cancers, lung cancers, lymphomas—though these cancers affect different parts of the body, they can all be treated with one of the latest therapies medicine has to offer: checkpoint inhibitors.

This article is based on a poster originally authored by Smith Frank, Boute Melodie, Ruez Richard, Amandine Gerstenberg and Ramos Corinne. This poster is being hosted on this website in its raw form, ...

Three years after enrolling its first patients, a consortium of researchers examining the growing issue of immune-related adverse events due to immune checkpoint inhibitor cancer therapy released a ...

Oncodermatology is evolving with nonsurgical approaches and immune checkpoint inhibitors, improving outcomes in aggressive ...